FY2024 · ended Dec 31, 2024 · Revenue $178.03M, +195.3% YoY · Filed Mar 24, 2025
Adaptimmune Therapeutics PLC (ADAPY) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In fiscal 2024, which ended Dec 31, 2024, it reported revenue of $178.0 million and a net loss of $70.8 million. Free cash flow was -$74.1 million. As of Jun 30, 2025 it held $26.1 million in cash and investments and $48.7 million in total debt.
Revenue (TTM)
$65.08M
-54.0% vs year-ago TTM
Net income (TTM)
$-169.76M
-134.1% vs year-ago TTM
Operating cash flow (TTM)
$-190.03M
-328.1% vs year-ago TTM
Free cash flow (TTM)
$-191.67M
-316.4% vs year-ago TTM
EPS (TTM)
$-0.11
-119.3% vs year-ago TTM
Dividend per share
None
Shares outstanding
1.54B
+4.2% vs prior year
Net cash
$-22.62M
as of Jun 30, 2025
Operating margin
-252.3%
FY 2025
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ADAPY (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- United Kingdom
- Headquarters
- Abingdon, Oxfordshire
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1621227
- Former names
- Adaptimmune Ltd (until Mar 17, 2015)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $178.0M | $60.3M | $27.1M | $6.1M | $4.0M |
| Operating income | -$68.8M | -$139.7M | -$164.0M | -$162.2M | -$133.4M |
| Net income | -$70.8M | -$113.9M | -$165.5M | -$158.1M | -$130.1M |
| Diluted EPS | -$0.05 | -$0.09 | -$0.17 | -$0.17 | — |
| Operating cash flow | -$73.2M | -$140.9M | -$141.8M | $10.7M | -$53.6M |
| Free cash flow | -$74.1M | -$145.6M | -$171.3M | $2.2M | -$55.9M |
| Total assets | $246.0M | $282.6M | $328.9M | $469.5M | $451.1M |
| Total liabilities | $234.1M | $243.1M | $247.0M | $263.6M | $109.9M |
| Stockholders' equity | $11.8M | $39.5M | $81.9M | $206.0M | $341.2M |
| Cash and investments | $151.6M | $146.9M | $204.6M | $369.6M | $368.2M |
| Total debt | $78.2M | $25.2M | $23.1M | $25.5M | $23.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Listing notice, Regulation FD disclosure
|
Oct 20, 2025 | Oct 15, 2025 |
| 8-K |
Current report
Listing notice
|
Sep 26, 2025 | Sep 22, 2025 |
| 8-K |
Current report
Listing notice
|
Sep 12, 2025 | Sep 11, 2025 |
| 8-K |
Current report
Officer or director change
|
Sep 8, 2025 | Sep 6, 2025 |
| 8-K |
Current report
Officer or director change
|
Aug 29, 2025 | Aug 29, 2025 |
| 8-K |
Current report
Officer or director change
|
Aug 15, 2025 | Aug 15, 2025 |
All 808 Adaptimmune Therapeutics PLC SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.